the European Haemophilia Consortium and the National Hemophilia Foundation said Sanofi had voluntary put the full development programme on hold “due to the identification of new adverse events”.

Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit Therapeutics could keep its momentum going with positive clinical results for cancer ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Hemophilia is a rare genetic condition that prevents your blood from clotting and can lead to bleeding problems. People with hemophilia can have bleeding episodes that happen without trauma and ...

Sanofi and Sobi's haemophilia partnership has been under competitive pressure from new therapies like Roche's antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate ...

In the wake of the COVID-19 pandemic, which acclimated many workers to at-home or hybrid work models, French drugmaker Sanofi concluded that the traditional office paradigm was on its way out.

Sanofi SAN0.61%increase; green up pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL-0.25%decrease; red down pointing triangle for approximately $470 million, a deal ...

CFOTO / Future Publishing via Getty Images A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Additionally, Sanofi will also pay Vigil shareholders $2 per share in cash on the first commercial sale of its Alzheimer’s drug- VG-3927. VG-3927 is an early-stage drug that is set to be ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...

Jivi antihemophilic factor is now approved for children aged 7-12 with hemophilia A, expanding its previous approval for older patients. Hemophilia A is more common than hemophilia B, with early ...